{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=80",
    "query": {
      "intervention": "serum sample",
      "page": 80
    },
    "page_size": 10
  },
  "pagination": {
    "page": 80,
    "page_size": 10,
    "total_count": 8381,
    "total_pages": 839,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=81&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=serum+sample&page=79&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-31T04:55:18.870Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00538291",
      "title": "Cetuximab and Capecitabine in Treating Patients With Metastatic Colorectal Cancer That Failed Irinotecan Treatment",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "cetuximab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "capecitabine",
          "type": "DRUG"
        },
        {
          "name": "gene expression analysis",
          "type": "GENETIC"
        },
        {
          "name": "microarray analysis",
          "type": "GENETIC"
        },
        {
          "name": "polymorphism analysis",
          "type": "GENETIC"
        },
        {
          "name": "reverse transcriptase-polymerase chain reaction",
          "type": "GENETIC"
        },
        {
          "name": "immunohistochemistry staining method",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "GENETIC",
        "OTHER"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2005-08",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-08-28",
      "last_synced_at": "2026-10-31T04:55:18.870Z",
      "location_count": 2,
      "location_summary": "Duarte, California • Pasadena, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00538291"
    },
    {
      "nct_id": "NCT00853385",
      "title": "A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Rheumatoid Arthritis"
      ],
      "interventions": [
        {
          "name": "CP-690,550",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        },
        {
          "name": "Biologic TNFi",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "BIOLOGICAL"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 717,
      "start_date": "2009-05",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2013-01-18",
      "last_synced_at": "2026-10-31T04:55:18.870Z",
      "location_count": 38,
      "location_summary": "Gilbert, Arizona • Glendale, Arizona • Mesa, Arizona + 33 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00853385"
    },
    {
      "nct_id": "NCT01227018",
      "title": "PhII Study STA-9090 as Second or Third-Line Therapy for Metastatic Pancreas Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Adenocarcinoma of the Pancreas",
        "Recurrent Pancreatic Cancer",
        "Stage IV Pancreatic Cancer"
      ],
      "interventions": [
        {
          "name": "STA-9090",
          "type": "DRUG"
        },
        {
          "name": "Radiologic imaging",
          "type": "RADIATION"
        },
        {
          "name": "blood draw",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "Vanderbilt-Ingram Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2010-12",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2014-07-23",
      "last_synced_at": "2026-10-31T04:55:18.870Z",
      "location_count": 2,
      "location_summary": "Memphis, Tennessee • Nashville, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01227018"
    },
    {
      "nct_id": "NCT05568134",
      "title": "Alternate Measures of Glucose During OGTT Testing for CFRD",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cystic Fibrosis",
        "Cystic Fibrosis-related Diabetes"
      ],
      "interventions": [
        {
          "name": "Oral glucose tolerance test",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "10 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "10 Years and older"
      },
      "enrollment_count": 14,
      "start_date": "2023-07-17",
      "completion_date": "2024-12-13",
      "has_results": false,
      "last_update_posted_date": "2025-02-24",
      "last_synced_at": "2026-10-31T04:55:18.870Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05568134"
    },
    {
      "nct_id": "NCT07702032",
      "title": "Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Left-sided Colorectal Cancer"
      ],
      "interventions": [
        {
          "name": "Petosemtamab",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI",
          "type": "DRUG"
        },
        {
          "name": "mFOLFOX6",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genmab",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 960,
      "start_date": "2026-08-11",
      "completion_date": "2031-09",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-10-31T04:55:18.870Z",
      "location_count": 7,
      "location_summary": "Hot Springs, Arkansas • Los Angeles, California • Savannah, Georgia + 4 more",
      "locations": [
        {
          "city": "Hot Springs",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Savannah",
          "state": "Georgia"
        },
        {
          "city": "Warner Robins",
          "state": "Georgia"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07702032"
    },
    {
      "nct_id": "NCT03307616",
      "title": "Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Dedifferentiated Liposarcoma",
        "Recurrent Dedifferentiated Liposarcoma",
        "Recurrent Undifferentiated Pleomorphic Sarcoma",
        "Resectable Dedifferentiated Liposarcoma",
        "Resectable Undifferentiated Pleomorphic Sarcoma",
        "Undifferentiated Pleomorphic Sarcoma"
      ],
      "interventions": [
        {
          "name": "Ipilimumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Radiation Therapy",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "RADIATION"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 32,
      "start_date": "2017-10-04",
      "completion_date": "2027-10-31",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-31T04:55:18.870Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03307616"
    },
    {
      "nct_id": "NCT00022672",
      "title": "A Study to Evaluate the Efficacy and Safety of Herceptin® (Trastuzumab) in Combination With Arimidex® (Anastrozole) an Aromatase Inhibitor Compared to Arimidex® Alone in Patients With Metastatic Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "trastuzumab (Herceptin®)",
          "type": "DRUG"
        },
        {
          "name": "anastrazole (Arimidex®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 208,
      "start_date": "2001-01",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2013-06-13",
      "last_synced_at": "2026-10-31T04:55:18.870Z",
      "location_count": 20,
      "location_summary": "Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 16 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Vallejo",
          "state": "California"
        },
        {
          "city": "Gainsville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00022672"
    },
    {
      "nct_id": "NCT07290439",
      "title": "Improving Maternal and Child Health Through Point-of-care STI Testing",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Treponema Pallidum Infection",
        "Chlamydia Trachomatis Infection",
        "Neisseria Gonorrheae Infection",
        "Trichomonas Vaginalis Vaginitis",
        "Sexually Transmitted Infection"
      ],
      "interventions": [
        {
          "name": "Point-of-care STI tests",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Standard of care STI testing",
          "type": "DIAGNOSTIC_TEST"
        }
      ],
      "intervention_types": [
        "DIAGNOSTIC_TEST"
      ],
      "sponsor": "Emory University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "Female only"
      },
      "enrollment_count": 756,
      "start_date": "2026-08-11",
      "completion_date": "2030-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-19",
      "last_synced_at": "2026-10-31T04:55:18.870Z",
      "location_count": 1,
      "location_summary": "Atlanta, Georgia",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07290439"
    },
    {
      "nct_id": "NCT04056910",
      "title": "Ivosidenib (AG-120) With Nivolumab in IDH1 Mutant Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumor",
        "IDH1 Mutation",
        "Glioma"
      ],
      "interventions": [
        {
          "name": "ivosidenib and nivolumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jason J. Luke, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 15,
      "start_date": "2021-09-20",
      "completion_date": "2023-11-13",
      "has_results": true,
      "last_update_posted_date": "2025-02-27",
      "last_synced_at": "2026-10-31T04:55:18.870Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04056910"
    },
    {
      "nct_id": "NCT00854139",
      "title": "Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Myeloma",
        "End Stage Renal Disease"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide, anti-thymocyte globulin",
          "type": "DRUG"
        },
        {
          "name": "Kidney transplant",
          "type": "PROCEDURE"
        },
        {
          "name": "Thymic irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Bone marrow transplant from a related donor",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 10,
      "start_date": "2001-08",
      "completion_date": "2014-07",
      "has_results": false,
      "last_update_posted_date": "2020-03-04",
      "last_synced_at": "2026-10-31T04:55:18.870Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00854139"
    }
  ]
}